Gradually glycosylated protein C mutants (Arg178Gln and Cys331Arg) are degraded by proteasome after mannose trimming.
Proteins that fail to attain their correct three-dimensional structure are retained in the endoplasmic reticulum (ER) and eventually degraded within the cells. We investigated the degradation of mutant proteins, using naturally occurring protein C (PC) mutants (Arg178Gln and Cys331Arg) which lead to congenital deficiencies. Chinese hamster ovary (CHO) cells were transfected with normal or mutant expression vectors. The introduction of mutation at Asn329 of an unusual sequence Asn-X-Cys for N-linked glycosylation revealed that the mutation at Cys331, which may preclude a formation of disulfide bond with Cys345, resulted in no addition of N-linked oligosaccharides at Asn329. PC mutants with 4 glycosylation sites were gradually glycosylated in the ER, and the fourth glycosylation site is less accessible for glycosylation as reported for PC in plasma. The half lives of PC178 and PC331 mutants were about 5 and 4 h, respectively. PC mutants were degraded, but the degradation was inhibited by inhibitors for proteasome. Mannose trimming of N-linked oligosaccharides after glucose removal targeted PC mutants for degradation by proteasomes. And also the inhibition of glucose trimming immediately led to mannose trimming, resulting in the accelerated degradation of PC mutants. These degradations were inhibited by mannosidase I inhibitor, kifunensine. These results indicate that the initiation of mannose trimming by mannosidase I leads to the proteasomemediated degradation of glucose-trimmed or untrimmed PC mutants.
Nakahara
Masako
M
Laboratory Molecular Genetics, Graduate School of Health Sciences, Tokyo, Japan.
Koyama
Takatoshi
T
Nakazawa
Fumie
F
Nishio
Miwako
M
Shibamiya
Aya
A
Hirosawa
Shinsaku
S
D000818:Animals; D001120:Arginine / Q000737:chemistry; D001216:Asparagine / Q000737:chemistry; D001665:Binding Sites; D016466:CHO Cells; D006224:Cricetinae; D003545:Cysteine / Q000737:chemistry; D018076:DNA, Complementary / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004721:Endoplasmic Reticulum / Q000378:metabolism*; D005822:Genetic Vectors; D005947:Glucose / Q000378:metabolism; D005973:Glutamine / Q000737:chemistry; D006031:Glycosylation; D047468:Immunoprecipitation; D008358:Mannose / Q000737:chemistry*; D009154:Mutation; D009844:Oligosaccharides / Q000737:chemistry; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D061988:Proteasome Inhibitors; D011486:Protein C / Q000235:genetics*; D011994:Recombinant Proteins / Q000737:chemistry; D013997:Time Factors; D014162:Transfection
D018076:DNA, Complementary; D009844:Oligosaccharides; D061988:Proteasome Inhibitors; D011486:Protein C; D011994:Recombinant Proteins; D005973:Glutamine; D001216:Asparagine; D001120:Arginine; D046988:Proteasome Endopeptidase Complex; D005947:Glucose; D003545:Cysteine; D008358:Mannose